Rapid Micro Biosystems (RPID) Current Deferred Revenue (2020 - 2026)

Rapid Micro Biosystems has disclosed Current Deferred Revenue across 7 years of filings, most recently posting $6.6 million for Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $6.6 million, up 8.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.6 million (up 8.34% YoY), and the FY2025 annual result was $4.7 million, down 28.26% from the prior year.
• Current Deferred Revenue came in at $6.6 million for Q1 2026 at Rapid Micro Biosystems, up from $4.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $6.6 million in Q1 2026 to a low of $3.4 million in Q3 2022.
• The 5-year median for Current Deferred Revenue is $5.4 million (2024), against an average of $5.2 million.
• Across the five-year window, Current Deferred Revenue surged 42.21% in 2022 and dropped 28.26% in 2025, its largest moves.
• Rapid Micro Biosystems' Current Deferred Revenue stood at $4.7 million in 2022, then rose by 27.11% to $6.0 million in 2023, then grew by 10.46% to $6.6 million in 2024, then slipped by 28.26% to $4.7 million in 2025, then surged by 39.42% to $6.6 million in 2026.
• The last three Current Deferred Revenue figures came in at $6.6 million (Q1 2026), $4.7 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.